Unknown

Dataset Information

0

Development of Inhibitors against Mycobacterium abscessus tRNA (m1G37) Methyltransferase (TrmD) Using Fragment-Based Approaches.


ABSTRACT: Mycobacterium abscessus (Mab) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. Mab pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m1G37) methyltransferase (TrmD) is a promising target for novel antibiotics. It is essential in Mab and other mycobacteria, improving reading frame maintenance on the ribosome to prevent frameshift errors. In this work, a fragment-based approach was employed with the merging of two fragments bound to the active site, followed by structure-guided elaboration to design potent nanomolar inhibitors against Mab TrmD. Several of these compounds exhibit promising activity against mycobacterial species, including Mycobacterium tuberculosis and Mycobacterium leprae in addition to Mab, supporting the use of TrmD as a target for the development of antimycobacterial compounds.

SUBMITTER: Whitehouse AJ 

PROVIDER: S-EPMC6691401 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Development of Inhibitors against <i>Mycobacterium abscessus</i> tRNA (m<sup>1</sup>G37) Methyltransferase (TrmD) Using Fragment-Based Approaches.

Whitehouse Andrew J AJ   Thomas Sherine E SE   Brown Karen P KP   Fanourakis Alexander A   Chan Daniel S-H DS   Libardo M Daben J MDJ   Mendes Vitor V   Boshoff Helena I M HIM   Floto R Andres RA   Abell Chris C   Blundell Tom L TL   Coyne Anthony G AG  

Journal of medicinal chemistry 20190719 15


<i>Mycobacterium abscessus</i> (<i>Mab</i>) is a rapidly growing species of multidrug-resistant nontuberculous mycobacteria that has emerged as a growing threat to individuals with cystic fibrosis and other pre-existing chronic lung diseases. <i>Mab</i> pulmonary infections are difficult, or sometimes impossible, to treat and result in accelerated lung function decline and premature death. There is therefore an urgent need to develop novel antibiotics with improved efficacy. tRNA (m<sup>1</sup>G  ...[more]

Similar Datasets

| S-EPMC6054489 | biostudies-literature
| S-EPMC156765 | biostudies-literature
| S-EPMC2995409 | biostudies-literature
| S-EPMC412112 | biostudies-literature
| S-EPMC3789996 | biostudies-literature
| S-EPMC4835159 | biostudies-literature
| S-EPMC5217690 | biostudies-literature
| S-EPMC4534213 | biostudies-literature
| S-EPMC5444174 | biostudies-literature
| S-EPMC4576034 | biostudies-literature